Regentis Biomaterials Ltd. (AMEX:RGNT) Financings
Financings
| Raise | Date |
|---|---|
| Private placement of ordinary shares (or pre-funded warrants) with ordinary warrants Announced: about US$6.5M · US$3.5 a share · Warrants at US$4.2 for 60 months · ThinkEquity Dealers: ThinkEquity (lead) Use of proceeds: GelrinC pivotal trial and FDA PMA preparation, Gelrin platform, manufacturing scale-up, European market entry, working capital | Jun 18, 2026 |
| Public offering of ordinary shares Closed: US$10M raised · US$8 a share · ThinkEquity Dealers: ThinkEquity (lead) Use of proceeds: Development activities including completing its pivotal trial and PMA submission prep for GelrinC, plus debt repayment and deferred compensation | Dec 5, 2025 |